Drug intelligence / Profile preview

DNP-019

Development stage: Preclinical
Lead developer: DiNonA
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

DNP-019 is an investigational **monoclonal antibody** developed by **DiNonA** as a potential therapeutic for **COVID-19**. Publicly available information indicates it was advanced as a SARS-CoV-2 antibody program and that **Samsung Biologics** entered a development and manufacturing collaboration to support cell line, process development, and production activities. Specific target, epitope, and detailed mechanism of action have not been clearly disclosed in reliable public sources, so it is best characterized as an early-stage antiviral antibody candidate for coronavirus infection.

Beyond the preview

Go deeper on DNP-019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNP-019.

Explore the full profile